FDA Clears Dexcom’s Stelo Glucose Biosensor System as First OTC Continuous Glucose Monitor for Non-Insulin-Using Children Ages 2+

August 2, 2026

Weence.com USA

Overview

On June 12, 2026, the FDA approved Dexcom’s Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM) for children aged 2 and older who do not use insulin. This system, which pairs a wearable sensor with an app, provides glucose readings and trend data every 15 minutes for 15 days. While it helps users understand the impact of diet and activity on blood glucose, it is not intended for low glucose alerts or guiding medication adjustments.

In Depth

Key Findings

On June 12, 2026, the U.S. Food and Drug Administration (FDA) granted approval to Dexcom Inc.’s Stelo Glucose Biosensor System as the first over-the-counter (OTC) continuous glucose monitor (CGM) specifically for non-insulin-using children aged 2 and older. This landmark approval significantly enhances accessibility to glucose monitoring for a distinct pediatric patient population.

Technical / Clinical Details

The Stelo Glucose Biosensor System is a non-invasive device comprising a small wearable sensor and a synchronized smartphone application. The sensor is affixed to the skin and wirelessly transmits real-time glucose data for display on the app.
The system is designed for continuous use over 15 days, automatically measuring and presenting glucose levels and trend information every 15 minutes. This consistent data stream empowers patients and their caregivers to gain a deeper understanding of how factors like diet, exercise, and other daily activities influence blood glucose dynamics.
A crucial aspect of this OTC CGM is its specific targeting of children aged 2 and above who are not on insulin therapy. This addresses a distinct market segment, differentiating it from traditional prescription-based CGMs primarily intended for insulin-dependent diabetic patients.
However, it is important to note that the Stelo system does not incorporate a low blood glucose alert function, nor is it cleared for direct use in making insulin dosage adjustments or other medication decisions. Its primary role is as an adjunctive tool for glucose trend awareness and general health management.

Background & Context

Continuous glucose monitors have revolutionized diabetes management, but their availability has historically been limited primarily to insulin-using patients, often requiring a prescription. The FDA’s OTC approval of Stelo addresses an unmet need for broader patient access, particularly within the pediatric population who do not rely on insulin. This move signals a broader trend where digital health and wearable technologies are evolving into direct-to-consumer healthcare solutions, requiring less direct oversight from medical professionals while still providing valuable health insights.

Strategic Significance & Outlook

The OTC approval of the Stelo Glucose Biosensor System reflects the expanding CGM market and the growing demand for personalized health management tools. This development is expected to empower non-insulin-using children and their families to take a more proactive role in managing their glucose trends, thereby contributing to the establishment of healthier lifestyle habits. Going forward, it is anticipated that other CGM manufacturers may seek to enter the OTC market, leading to accelerated technological innovation and increased market competition in this rapidly evolving sector of digital health.

Source: https://weence.com/nutrition-dietary-guidance/fda-cleared-an-otc-cgm-for-kids-using-glucose-trends-safely/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.